Ticker Scout
← Cencora, Inc. (COR)

Cencora, Inc. (COR) Q3 FY2026 8-K Filings and Company Events

CIK 0001140859 · NYSE · Latest period: Q3 FY2026 (ended 2026-06-30, 10-Q accession 0001140859-26-000034) · Annual report: FY2025 10-K (filed 2025-11-25, accession 0001140859-25-000131) · Next expected filing: 10-K ~2026-11-24

More for Cencora: Company index · Financial statements · 10-K and 10-Q summary

PeriodQ3 FY2026

Published

This page digests the material Form 8-K filings Cencora, Inc. (COR) has made over roughly the trailing five quarters: earnings releases, management and board changes, capital returns, financing, and governance actions. Each item cites the SEC accession number of the filing it came from. It is current through Q3 FY2026, the period ended 2026-06-30, as reported in the 10-Q filed with the SEC.

Filings that contain financial statements

  • Form 8-K filed August 5, 2026 (accession 0001140859-26-000032): Exhibit 99.1 earnings release for the fiscal third quarter ended June 30, 2026. It holds condensed consolidated statements of operations, a condensed consolidated balance sheet and condensed consolidated statements of cash flows (nine months ended June 30, 2026), with GAAP to non-GAAP reconciliations.
  • Form 8-K filed May 6, 2026 (accession 0001140859-26-000018): Exhibit 99.1 earnings release for the fiscal second quarter ended March 31, 2026, with condensed consolidated statements of operations, balance sheet and statements of cash flows (six months ended March 31, 2026).
  • Form 8-K filed February 10, 2026 (accession 0001140859-26-000012): Exhibit 99.1 recasts Items 1, 7 and 8 of the fiscal 2025 Form 10-K (year ended September 30, 2025) for the new segment structure. It carries the full fiscal 2025 financial statements and notes. The company states the audited consolidated statements are not restated; only segment results are revised.
  • Form 8-K filed February 4, 2026 (accession 0001140859-26-000004): Exhibit 99.1 earnings release for the fiscal first quarter ended December 31, 2025, with condensed consolidated statements of operations, balance sheet and statements of cash flows (three months ended December 31, 2025), with GAAP to non-GAAP reconciliations.
  • Form 8-K filed November 5, 2025 (accession 0001140859-25-000128): Exhibit 99.1 earnings release for the fiscal fourth quarter and year ended September 30, 2025, with condensed consolidated statements of operations, balance sheet and statements of cash flows. Exhibit 99.2 furnishes unaudited revised fiscal 2025 and 2024 segment revenue and operating income under the new reporting structure.

Earnings and guidance

  • August 12, 2026 – Walgreens volume (0001104659-26-094676). Beginning July 1, 2026, certain Walgreens volume serviced outside the prime vendor agreement began moving away from Cencora. The prime vendor agreement, described as the vast majority of the Walgreens business, is unchanged. The company said this was contemplated in its August 5 commentary on U.S. Healthcare Solutions and reaffirmed fiscal 2026 adjusted diluted EPS guidance of $17.75–$17.95.
  • August 5, 2026 – fiscal Q3 results (0001140859-26-000032). Revenue $84.8 billion, up 5.1%. GAAP diluted EPS $3.94 (prior year $3.52); adjusted diluted EPS $4.48, up 12.0% from $4.00. Fiscal 2026 adjusted diluted EPS guidance raised from $17.70–$17.90 to $17.75–$17.95. The company repurchased $1 billion of shares in the quarter, the amount it had expected to complete by the end of calendar 2026. Operating expenses included a $102.0 million reduction of opioid liability tied to dismissal of opioid litigation. Growth drivers cited include the February 2026 OneOncology acquisition and GLP-1 sales (lower gross margin).
  • May 27, 2026 release (8-K filed May 29, 0001104659-26-068357). Guidance reaffirmed at $17.70–$17.90, reflecting a May 21 adjustment from $17.65–$17.90 for opportunistic share repurchases; long-term targets reaffirmed (adjusted operating income growth 7%–10%, adjusted diluted EPS growth 10%–14%).
  • May 6, 2026 – fiscal Q2 results (0001140859-26-000018). Revenue $78.4 billion, up 3.8%. GAAP diluted EPS $8.40 (prior year $3.68); adjusted diluted EPS $4.75. Guidance raised from $17.45–$17.75 to $17.65–$17.90. The company said it expected to repurchase $1 billion of shares by the end of calendar 2026.
  • March 17, 2026 (0001104659-26-029039). Fiscal 2026 adjusted diluted EPS guidance of $17.45–$17.75 reaffirmed.
  • February 4, 2026 – fiscal Q1 results (0001140859-26-000004). Revenue $85.9 billion, up 5.5%. GAAP diluted EPS $2.87 (prior year $2.50); adjusted diluted EPS $4.08, up 9.4% from $3.73. Adjusted operating income guidance for fiscal 2026 raised from growth of 8%–10% to 11.5%–13.5%, primarily to reflect the completed OneOncology acquisition and U.S. Healthcare Solutions performance; adjusted diluted EPS guidance reaffirmed at $17.45–$17.75; net interest expense guidance $480–$500 million (previously $315–$335 million). Operating expenses included a $249.5 million impairment related to the U.S. Consulting Services business, classified as held for sale, partly offset by a litigation and opioid-related credit of $86.8 million. The Item 7.01 text reports OneOncology acquired on February 2, 2026 for total cash consideration of approximately $4.6 billion, funded by new debt, with results consolidated in U.S. Healthcare Solutions.
  • November 5, 2025 – fiscal Q4 and full-year 2025 results (0001140859-25-000128). Fourth-quarter revenue $83.7 billion, up 5.9%; GAAP diluted EPS $(1.75) including a $723.9 million PharmaLex goodwill impairment; adjusted diluted EPS $3.84. Fiscal 2025 revenue $321.3 billion, up 9.3%; GAAP diluted EPS $7.96; adjusted diluted EPS $16.00. Initial fiscal 2026 guidance: adjusted diluted EPS $17.45–$17.75, adjusted operating income growth of 8%–10%, net interest expense $315–$335 million. Long-term guidance raised to adjusted operating income growth of 6%–9% and adjusted diluted EPS growth of 9%–13%. Quarterly dividend raised 9% from $0.55 to $0.60 per share (declared November 4, payable December 1, 2025). The filing also announces the new reporting structure (U.S. Healthcare Solutions, International Healthcare Solutions, Other) beginning fiscal 2026 Q1.

M&A and portfolio

  • OneOncology – signed December 12, 2025, announced December 15 (0001104659-25-120852). Agreement to acquire the majority of the equity interests Cencora did not own from TPG and other shareholders for about $3.6 billion plus retirement of $1.3 billion of existing OneOncology corporate debt, about $5.0 billion total cash consideration (enterprise value $7.4 billion); expected close by the end of fiscal Q2 2026. The release reiterated fiscal 2026 guidance (excluding OneOncology), said share repurchases were paused, making the lower half of the $17.45–$17.75 range more likely, expected the deal to be approximately neutral to adjusted diluted EPS in the first twelve months, and raised long-term guidance to adjusted operating income growth of 7%–10% with adjusted diluted EPS growth of 10%–14%.
  • OneOncology – closed. Cencora acquired the majority of the outstanding OneOncology equity interests it did not already own on February 2, 2026, at total fair value consideration of $7,387.1 million, including $4,648.7 million of cash; a $1,086.6 million remeasurement gain was recorded (Form 10-Q filed August 5, 2026, accession 0001140859-26-000034). Financing: $3.0 billion of senior notes and $1.5 billion of term loans (see Debt).
  • MWI Animal Health merger with Covetrus – signed, pending. Definitive agreement dated February 17, 2026 (8-K filed February 18, accession 0001104659-26-016785). Enterprise value for MWI $3.5 billion; Cencora to receive $1.25 billion upfront cash, $800 million of perpetual PIK preferred units and $1.45 billion of common units, for about 34.3% ownership of CVET TopCo, LP. Subject to customary closing conditions including regulatory approvals; guidance does not contemplate a fiscal 2026 close. On May 20, 2026 the company received an FTC request for additional information; the 10-Q (0001140859-26-000034) says the transaction is still under review, and MWI is classified as held for sale.
  • EyeSouth Partners retina business – signed, pending. Definitive agreement entered March 21, 2026, announced March 23 (0001104659-26-033022): $1.1 billion, to join Retina Consultants of America; expected slightly accretive to adjusted diluted EPS in the first twelve months after closing. Subject to regulatory approvals; guidance does not contemplate a fiscal 2026 close. The Form 10-Q filed August 5, 2026 does not report it as closed, and no filing through September 25, 2026 reports a closing.
  • U.S. Consulting Services – divested April 2026. Per the Q3 earnings release and Form 10-Q, the business was divested in April 2026; fiscal 2026 impairments of $249.5 million including goodwill were recorded on it ($165.7 million of goodwill per the 10-Q note).
  • Segment realignment (8-K February 10, 2026, 0001140859-26-000012). Beginning fiscal 2026 Q1 the company reports U.S. Healthcare Solutions, International Healthcare Solutions and Other (MWI Animal Health, Profarma, U.S. Consulting Services and parts of PharmaLex, businesses for which it is exploring strategic alternatives).

Debt and capital

  • January 12, 2026 – OneOncology financing agreements (8-K filed January 16, 0001104659-26-004524). Revolving credit agreement amended to raise commitments by $1.0 billion to $5.5 billion. New $1.5 billion senior unsecured Term Credit Agreement (JPMorgan Chase as agent) in two tranches, $500 million maturing two years and $1.0 billion three years after drawing. New $3.0 billion 364-Day Term Credit Agreement (Citibank as agent), maturing 364 days after drawing. Both term facilities are funded only on consummation of the acquisition and priced at Term SOFR or Daily Simple SOFR plus 75 to 125 basis points (term loan) and 87.5 to 112.5 basis points (364-day loan). The $4.5 billion of bridge financing commitments was reduced to zero.
  • February 10–13, 2026 – $3.0 billion senior notes. Priced February 10 (0001104659-26-013465) and closed February 13 (0001104659-26-015272): $500 million 3.950% due 2029, $500 million 4.250% due 2030, $500 million 4.600% due 2033, $1.0 billion 4.900% due 2036 and $500 million 5.650% due 2056. Proceeds repaid the 364-Day Term Credit Agreement used for OneOncology.
  • July 31, 2026 – credit facility amendments (8-K filed August 5, 0001104659-26-090691). Multi-currency revolver amended and restated: commitments up from $5.5 billion to $7.0 billion, maturity extended to July 2031, pricing 69.5 to 110 basis points over term benchmark rates. Receivables securitization facility reduced from $1.5 billion to $1.0 billion, with the accordion raised from $500 million to $1.0 billion.
  • Term loans (10-Q, 0001140859-26-000034). $400 million repaid in the June quarter and the remaining $400 million of the term loan due 2027 repaid in July 2026.
  • Share repurchases. A new $2.0 billion authorization was approved in May 2026 (10-Q, 0001140859-26-000034); $1 billion was repurchased in fiscal Q3.

Management and board

  • Director appointment. Ellen G. Cooper (Chairman, President and CEO of Lincoln Financial) appointed an independent director effective January 20, 2026, increasing the Board from ten to eleven; no committee assignment at the time (0001104659-26-005604, January 22, 2026).
  • Annual meeting, March 5, 2026 (0001140859-26-000014). All eleven directors elected; say-on-pay approved (156.9 million for, 11.4 million against); Ernst & Young ratified.
  • CFO transition. James F. Cleary's retirement announced March 17, 2026 (0001104659-26-029039); Eva C. Boratto (previously CFO of Bath & Body Works) appointed CFO effective June 29, 2026, with a $1,000,000 base salary, a $2,000,000 sign-on bonus subject to repayment and a $6,000,000 RSU award (0001104659-26-068357).
  • CHRO. Silvana Battaglia retired effective July 12, 2026; Samantha L. Hammock joined July 13, 2026 (0001104659-26-074102, June 15, 2026).
  • Board. Lorence H. Kim resigned August 13, 2026 with no disagreement stated (0001104659-26-097096). Robert E. Sanchez was appointed a director effective October 1, 2026, increasing the Board from ten to eleven (0001104659-26-110624, filed September 25, 2026).

FAQ · Cencora 8-K filings and events

What has Cencora, Inc. (COR) reported in its recent 8-K filings?

Cencora, Inc. (COR): Form 8-K filed August 5, 2026 (accession 0001140859-26-000032): Exhibit 99.1 earnings release for the fiscal third quarter ended June 30, 2026. It holds condensed consolidated statements of operations, a condensed consolidated balance sheet and condensed consolidated statements of cash flows (nine months ended June 30, 2026), with GAAP to non-GAAP reconciliations.

When does Cencora, Inc. (COR) next file with the SEC?

Cencora, Inc. (COR) is expected to file its next Form 10-K with the SEC on or around November 24, 2026. That date is a projection rather than a company-announced date: it is derived from Cencora, Inc.'s own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q3 FY2026, the period ended 2026-06-30, SEC accession 0001140859-26-000034.

Related companies

See every covered company and its filings data.

How this page was built

This page was built from 21 of Cencora, Inc.'s own filings with the SEC, read one at a time. Nothing on it is taken from news coverage, analyst commentary or another website. Their accession numbers are cited inline, so any statement here can be traced to the filing it came from and checked against sec.gov.

A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.

Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer

Built from Cencora, Inc.'s SEC filings by Ticker Scout; accession numbers are cited throughout so every figure can be checked against sec.gov. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.